FDA 483 - Aarti Drugs Limited - September 20, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Aarti Drugs Limited, an API manufacturer in Tarapur, India, was cited for significant deficiencies across its quality systems during an FDA inspection. The firm demonstrated inadequate procedures for investigating deviations and OOS results, scientifically unsound test methods, and a lack of stability-indicating test procedures for API expiry dating. Furthermore, the inspection revealed issues with cleaning validation, ineffective quality unit oversight, and insufficient internal audit processes, compounded by missing API distribution records.
ID · 1ebc39da-ee5b-49b2-8591-b0c5d0bb13d7